Real‐world performance of the MiniMed™ 670G system in Europe

• DOI: 10.1111/dom.14424
• Publication Date: 2021-05-09T00:43:59Z
• Authors: Julien Da Silva; Emanuele Bosi; Johan Jendle; Arcelia Arrieta; Javier Castaneda; Benyamin Grossman; Toni L. Cordero; John Shin; Ohad Cohen
• Keywords: Basal (medicine); Insulin delivery; tar (computing)

To evaluate the real-world performance of MiniMed 670G system in Europe, individuals with diabetes.Data uploaded from October 2018 to July 2020 by living Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage time spent within (TIR), below (TBR) above (TAR) glycaemic ranges, use insulin consumed users 10 or more days sensor data after initial Auto Mode start determined. Another analysis based on suboptimally (GMI > 8.0%) well-controlled < 7.0%) glycaemia pre-Auto initiation was also performed.Users (N = 14 899) a 81.4% achieved GMI 7.0% ± 0.4%, TIR 72.0% 9.7%, TBR less than 3.9 mmol/L 2.4% 2.1% TAR 25.7% 10%, initiating Mode. When compared initiation, reduced 0.3% 0.4% increased 9.6% 9.9% (P .0001 for both). Significantly improved control observed irrespective levels 8.0%. While total daily dose both groups, greater increase latter, an primarily due basal delivery. By contrast, decreased slightly users.Most 70% 7% while minimizing hypoglycaemia, environment. These international consensus-met outcomes enabled automated delivery meeting real-time requirements adapted each individual user.